Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 5/20 | 0.39 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.33 |
| ▸ | IDO1 | P14902 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CCR1 | P32246 | 1/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247898 | 0.79 | KDM4E (0.47) | ERN1METAP2KDM4ENPC1RAB9A | |
| SCHEMBL4731645 | 0.78 | METAP2 (0.40) | BRAFEIF2AK3METAP2KDM4ENPC1 | |
| SCHEMBL31358108 | 0.78 | METAP2 (0.40) | BRAFEIF2AK3METAP2KDM4ENPC1 | |
| SCHEMBL22718082 | 0.75 | NOS1 (0.32) | METAP2KDM4ENPC1RAB9AMEN1 | |
| SCHEMBL18953590 | 0.72 | METAP2 (0.36) | BRAFEIF2AK3METAP2IDO1MAPK10 | |
| SCHEMBL3497181 | 0.72 | NOS1 (0.46) | BRAFEIF2AK3METAP2IDO1MAPK10 | |
| SCHEMBL31190700 | 0.72 | NOS1 (0.46) | BRAFEIF2AK3METAP2MAPK10RIPK1 | |
| SCHEMBL29793750 | 0.72 | NOS1 (0.46) | BRAFEIF2AK3METAP2IDO1MAPK10 | |
| SCHEMBL806451 | 0.72 | MAPT (0.43) | BRAFEIF2AK3METAP2IDO1MAPK10 | |
| SCHEMBL261171 | 0.72 | NOS1 (0.55) | BRAFMETAP2NPC1RAB9AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| EP-2271649-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | Wyeth LLC (US) | 2011-01-12 | — | — | EP | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | WYETH (US) | 2010-02-04 | — | — | US | disclosed |
| WO-2009108838-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108838-A1 | BRIDGED, BICYCLIC HETEROCYCLIC OR SPIRO BICYCLIC HETEROCYCLIC DERIVATIVES OF PYRAZOLO[1,5-A]PYRIMIDINES, METHODS FOR PREPARATION AND USES THEREOF | WYETH (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | ERN1 3017/4885BRAF 4307/4885EIF2AK3 3343/4885 |
| US-20100029657-A1 | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof | BRAF, RAF1, ARAF | ERN1 477/4885BRAF 1/4885EIF2AK3 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.